Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for the supplementary application of the lactulose oral solution, facilitating a change in the marketing authorization holder. This approval follows an agreement with Beijing Minkangbaicao Medicine Technology Co., Ltd. for a technology transfer, including rights to marketing and sales. This strategic move is set to enhance Xinhua Pharmaceutical’s market presence in the pharmaceutical industry.
For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.